{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:10:54Z","timestamp":1791447054032,"version":"4.3.3"},"reference-count":152,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T00:00:00Z","timestamp":1654473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Ventricular arrhythmias (Vas) are a life-threatening condition and preventable cause of sudden cardiac death (SCD). With the increased utilization of implantable cardiac defibrillators (ICD), the focus of VA management has shifted toward reduction of morbidity from VAs and ICD therapies. Anti-arrhythmic drugs (AADs) can be an important adjunct therapy in the treatment of recurrent VAs. In the treatment of VAs secondary to structural heart disease, amiodarone remains the most well studied and current guideline-directed pharmacologic therapy. Beta blockers also serve as an important adjunct and are a largely underutilized medication with strong evidentiary support. In patients with defined syndromes in structurally normal hearts, AADs can offer tailored therapies in prevention of SCD and improvement in quality of life. Further clinical trials are warranted to investigate the role of newer therapeutic options and for the direct comparison of established AADs.<\/jats:p>","DOI":"10.3390\/jcm11113233","type":"journal-article","created":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T10:08:24Z","timestamp":1654510104000},"page":"3233","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Pharmacologic Management for Ventricular Arrhythmias: Overview of Anti-Arrhythmic Drugs"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0257-5994","authenticated-orcid":false,"given":"John","family":"Larson","sequence":"first","affiliation":[{"name":"Division of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Rich","sequence":"additional","affiliation":[{"name":"Division of Internal Medicine, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrish","family":"Deshmukh","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Cardiac Arrhythmia Service, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin C.","family":"Judge","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Cardiac Arrhythmia Service, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8608-8899","authenticated-orcid":false,"given":"Jackson J.","family":"Liang","sequence":"additional","affiliation":[{"name":"Division of Cardiovascular Medicine, Cardiac Arrhythmia Service, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,6]]},"reference":[{"key":"ref_1","first-page":"e210","article-title":"2017 AHA\/ACC\/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society","volume":"138","author":"Stevenson","year":"2018","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC)","volume":"36","author":"Priori","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.cjca.2014.11.023","article-title":"A systematic review and meta-analysis of the association between implantable cardioverter-defibrillator shocks and long-term mortality","volume":"31","author":"Proietti","year":"2015","journal-title":"Can. J. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.amjcard.2005.11.048","article-title":"Frequency and causes of implantable cardioverter-defibrillator therapies: Is device therapy proarrhythmic?","volume":"97","author":"Germano","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators (1997). A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N. Engl. J. Med., 337, 1576\u20131583.","DOI":"10.1056\/NEJM199711273372202"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/europace\/euq494","article-title":"Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients","volume":"13","author":"Borleffs","year":"2011","journal-title":"Europace"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.hrthm.2016.03.004","article-title":"Comparative effectiveness of antiarrhythmic drugs and catheter ablation for the prevention of recurrent ventricular tachycardia in patients with implantable cardioverter-defibrillators: A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Santangeli","year":"2016","journal-title":"Heart Rhythm"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.phrs.2019.03.020","article-title":"Anti-arrhythmic drug therapy in implantable cardioverter-defibrillator recipients","volume":"143","author":"AlTurki","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/j.1552-4604.1991.tb03695.x","article-title":"Significance of classifying antiarrhythmic actions since the cardiac arrhythmia suppression trial","volume":"31","year":"1991","journal-title":"J. Clin. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1161\/CIRCULATIONAHA.118.035455","article-title":"Modernized Classification of Cardiac Antiarrhythmic Drugs","volume":"138","author":"Lei","year":"2018","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/01.CIR.87.1.118","article-title":"Use-dependent prolongation of ventricular tachycardia cycle length by type I antiarrhythmic drugs in humans","volume":"87","author":"Kidwell","year":"1993","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJM199801013380107","article-title":"Quinidine","volume":"338","author":"Grace","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1749-6632.1984.tb14519.x","article-title":"Procainamide: Clinical Pharmacology and Efficacy against Ventricular Arrhythmiasa","volume":"432","author":"Giardina","year":"1984","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJM197904263001705","article-title":"Disopyramide","volume":"300","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1553-2712.2010.00680.x","article-title":"Amiodarone or procainamide for the termination of sustained stable ventricular tachycardia: An historical multicenter comparison","volume":"17","author":"Marill","year":"2010","journal-title":"Acad. Emerg. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0002-9149(96)00224-X","article-title":"Comparison of procainamide and lidocaine in terminating sustained monomorphic ventricular tachycardia","volume":"78","author":"Gorgels","year":"1996","journal-title":"Am. J. Cardiol."},{"key":"ref_17","first-page":"1329","article-title":"Randomized comparison of intravenous procainamide vs. intravenous amiodarone for the acute treatment of tolerated wide QRS tachycardia: The PROCAMIO study","volume":"38","author":"Ortiz","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM199308123290702","article-title":"A Comparison of Seven Antiarrhythmic Drugs in Patients with Ventricular Tachyarrhythmias","volume":"329","author":"Mason","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.hroo.2021.10.002","article-title":"Oral procainamide as pharmacological treatment of recurrent and refractory ventricular tachyarrhythmias: A single-center experience","volume":"2","author":"Toniolo","year":"2021","journal-title":"Heart Rhythm O2"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1161\/01.CIR.58.6.986","article-title":"Recurrent sustained ventricular tachycardia 3. Role of the electrophysiologic study in selection of antiarrhythmic regimens","volume":"58","author":"Horowitz","year":"1978","journal-title":"Circulation"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1161\/01.CIR.64.2.280","article-title":"Relationship between plasma levels of procainamide, suppression of premature ventricular complexes and prevention of recurrent ventricular tachycardia","volume":"64","author":"Myerburg","year":"1981","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1161\/01.CIR.101.5.510","article-title":"Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts","volume":"101","author":"Brugada","year":"2000","journal-title":"Circulation"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jacc.2008.10.044","article-title":"Characteristics of recurrent ventricular fibrillation associated with inferolateral early repolarization role of drug therapy","volume":"53","author":"Sacher","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1161\/CIRCULATIONAHA.118.038036","article-title":"Quinidine-Responsive Polymorphic Ventricular Tachycardia in Patients With Coronary Heart Disease","volume":"139","author":"Viskin","year":"2019","journal-title":"Circulation"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/europace\/euz290","article-title":"Quinidine-responsive out-of-hospital polymorphic ventricular tachycardia in patients with coronary heart disease","volume":"22","author":"Viskin","year":"2020","journal-title":"Europace"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1111\/jce.15260","article-title":"Efficacy and tolerability of quinidine as salvage therapy for monomorphic ventricular tachycardia in patients with structural heart disease","volume":"32","author":"Deshmukh","year":"2021","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1161\/01.CIR.84.5.1977","article-title":"Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias. A meta-analysis","volume":"84","author":"Morganroth","year":"1991","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jacep.2021.03.024","article-title":"Quinidine in the Management of Recurrent Ventricular Arrhythmias: A Reappraisal","volume":"7","author":"Li","year":"2021","journal-title":"JACC Clin. Electrophysiol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.jacc.2003.12.046","article-title":"Hydroquinidine therapy in Brugada syndrome","volume":"43","author":"Hermida","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/01.fjc.0000206437.27854.65","article-title":"Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome: Low-dose quinidine therapy as an adjunctive treatment","volume":"47","author":"Mizusawa","year":"2006","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.hrthm.2012.08.027","article-title":"Long-term efficacy of low doses of quinidine on malignant arrhythmias in Brugada syndrome with an implantable cardioverter-defibrillator: A case series and literature review","volume":"9","author":"Bonny","year":"2012","journal-title":"Heart Rhythm"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1161\/01.CIR.0000143159.30585.90","article-title":"Efficacy of quinidine in high-risk patients with Brugada syndrome","volume":"110","author":"Belhassen","year":"2004","journal-title":"Circulation"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1177\/000331978303400603","article-title":"A randomized, double-blind, parallel group comparison of disopyramide phosphate and quinidine in patients with cardiac arrhythmias","volume":"34","author":"Arif","year":"1983","journal-title":"Angiology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/0002-8703(85)90647-7","article-title":"Comparison of propafenone and disopyramide for treatment of chronic ventricular arrhythmias: Placebo-controlled, double-blind, randomized crossover study","volume":"109","author":"Naccarella","year":"1985","journal-title":"Am. Heart J."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/0002-9149(79)90405-3","article-title":"Suppression of ventricular arrhythmias with intravenous disopyramide and lidocaine: Efficacy comparison in a randomized trial","volume":"44","author":"Sbarbaro","year":"1979","journal-title":"Am. J. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0167-5273(91)90292-W","article-title":"Evaluation of disopyramide and mexiletine used alone and in combination for ventricular arrhythmias in patients with and without overt heart disease","volume":"32","author":"Tanabe","year":"1991","journal-title":"Int. J. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/BF00615957","article-title":"Efficacy of and adverse effects of disopyramide. Comparison of capsules, controlled release tablets and placebo in patients with chronic ventricular arrhythmias","volume":"29","author":"Ekelund","year":"1986","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with \u03b2-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ. Heart Fail"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e005152","DOI":"10.1161\/JAHA.116.005152","article-title":"Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients","volume":"6","author":"Adler","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/0002-8703(75)90162-3","article-title":"Electrophysiology and pharmacology of cardiac arrhythmias. V. Cardiac antiarrhythmic effects of lidocaine","volume":"89","author":"Rosen","year":"1975","journal-title":"Am. Heart J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1001\/archinte.1989.00390120056011","article-title":"Meta-analytic evidence against prophylactic use of lidocaine in acute myocardial infarction","volume":"149","author":"Hine","year":"1989","journal-title":"Arch. Intern. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/j.resuscitation.2012.07.008","article-title":"Wide variability in drug use in out-of-hospital cardiac arrest: A report from the resuscitation outcomes consortium","volume":"83","author":"Glover","year":"2012","journal-title":"Resuscitation"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1056\/NEJMoa013029","article-title":"Amiodarone as compared with lidocaine for shock-resistant ventricular fibrillation","volume":"346","author":"Dorian","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1514204","article-title":"Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest","volume":"374","author":"Kudenchuk","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0002-9149(81)90301-5","article-title":"Mexiletine for refractory-ventricular arrhythmias: Results using serial electrophysiologic testing","volume":"47","author":"DiMarco","year":"1981","journal-title":"Am. J. Cardiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/0002-8703(84)90413-7","article-title":"Mexiletine for recurring ventricular arrhythmias: Assessment by long-term electrocardiographic recordings and sequential electrophysiologic studies","volume":"108","author":"Flaker","year":"1984","journal-title":"Am. Heart J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/0002-9149(81)90191-0","article-title":"Mexiletine for ventricular arrhythmias","volume":"47","author":"Podrid","year":"1981","journal-title":"Am. J. Cardiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/0002-9149(90)91104-E","article-title":"Long-term effect of mexiletine on left ventricular function and relation to suppression of ventricular arrhythmia","volume":"66","author":"Singh","year":"1990","journal-title":"Am. J. Cardiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/0002-8703(84)90180-7","article-title":"Long-term mexiletine for ventricular arrhythmia","volume":"107","author":"Stein","year":"1984","journal-title":"Am. Heart J."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/clc.4960110304","article-title":"Chronic mexiletine therapy for suppression of ventricular arrhythmias","volume":"11","author":"Duke","year":"1988","journal-title":"Clin. Cardiol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Claro, J.C., Candia, R., Rada, G., Baraona, F., Larrondo, F., and Letelier, L.M. (2015). Amiodarone versus other pharmacological interventions for prevention of sudden cardiac death. Cochrane Database Syst. Rev., CD008093.","DOI":"10.1002\/14651858.CD008093.pub2"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.5603\/KP.2017.0189","article-title":"Efficacy and tolerability of mexiletine treatment in patients with recurrent ventricular tachyarrhythmias and implantable cardioverter-defibrillator shocks","volume":"75","author":"Sobiech","year":"2017","journal-title":"Kardiol. Pol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1080\/00015385.2021.1926628","article-title":"Mexiletine for ventricular arrhythmias in patients with chronic coronary syndrome: A cohort study","volume":"77","author":"Mugnai","year":"2021","journal-title":"Acta Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1513614","article-title":"Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs","volume":"375","author":"Sapp","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/FJC.0b013e31829651fe","article-title":"Mexiletine as an adjunctive therapy to amiodarone reduces the frequency of ventricular tachyarrhythmia events in patients with an implantable defibrillator","volume":"62","author":"Gao","year":"2013","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jacc.2015.12.033","article-title":"Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3","volume":"67","author":"Mazzanti","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198529010-00001","article-title":"Flecainide","volume":"29","author":"Holmes","year":"1985","journal-title":"Drugs"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1161\/01.CIR.102.7.748","article-title":"Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest: The Cardiac Arrest Study Hamburg (CASH)","volume":"102","author":"Kuck","year":"2000","journal-title":"Circulation"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1056\/NEJM199103213241201","article-title":"Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial","volume":"324","author":"Echt","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1161\/CIRCEP.114.002217","article-title":"Catecholaminergic polymorphic ventricular tachycardia in children: Analysis of therapeutic strategies and outcomes from an international multicenter registry","volume":"8","author":"Roston","year":"2015","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.hrthm.2013.08.011","article-title":"Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia","volume":"10","author":"Khoury","year":"2013","journal-title":"Heart Rhythm"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.hrthm.2014.11.009","article-title":"Cardiac late Na\u207a current: Proarrhythmic effects, roles in long QT syndromes, and pathological relationship to CaMKII and oxidative stress","volume":"12","author":"Belardinelli","year":"2015","journal-title":"Heart Rhythm"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1542-474X.2005.00077.x","article-title":"Safety and efficacy of flecainide in subjects with Long QT-3 syndrome (DeltaKPQ mutation): A randomized, double-blind, placebo-controlled clinical trial","volume":"10","author":"Moss","year":"2005","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"104274","DOI":"10.1016\/j.phrs.2019.104274","article-title":"Antiarrhythmic mechanisms of beta blocker therapy","volume":"146","author":"Grandi","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Al-Gobari, M., El Khatib, C., Pillon, F., and Gueyffier, F. (2013). \u03b2-Blockers for the prevention of sudden cardiac death in heart failure patients: A meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord., 13.","DOI":"10.1186\/1471-2261-13-52"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0735-1097(99)00234-X","article-title":"Beta-blocker use and survival in patients with ventricular fibrillation or symptomatic ventricular tachycardia: The Antiarrhythmics Versus Implantable Defibrillators (AVID) trial","volume":"34","author":"Exner","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0735-1097(98)00675-5","article-title":"Beta-adrenergic blocking agent use and mortality in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A post hoc analysis of the Studies of Left Ventricular Dysfunction","volume":"33","author":"Exner","year":"1999","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.jacc.2004.09.076","article-title":"Antiarrhythmic effect of carvedilol after acute myocardial infarction: Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial","volume":"45","author":"McMurray","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"BHAT Study Investigators (1982). A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA, 247, 1707\u20131714.","DOI":"10.1001\/jama.247.12.1707"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1161\/01.CIR.60.4.819","article-title":"Suppression of chronic ventricular arrhythmias with propranolol","volume":"60","author":"Woosley","year":"1979","journal-title":"Circulation"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0002-8703(89)90185-3","article-title":"Antiarrhythmic efficacy of solitary beta-adrenergic blockade for patients with sustained ventricular tachyarrhythmias","volume":"118","author":"Brodsky","year":"1989","journal-title":"Am. Heart J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1161\/01.CIR.84.2.558","article-title":"Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators","volume":"84","author":"Levine","year":"1991","journal-title":"Circulation"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jama.295.2.165","article-title":"Comparison of \u03b2-Blockers, Amiodarone Plus \u03b2-Blockers, or Sotalol for Prevention of Shocks From Implantable Cardioverter DefibrillatorsThe OPTIC Study: A Randomized Trial","volume":"295","author":"Connolly","year":"2006","journal-title":"JAMA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1161\/01.CIR.99.17.2268","article-title":"Amiodarone interaction with beta-blockers: Analysis of the merged EMIAT (European Myocardial Infarct Amiodarone Trial) and CAMIAT (Canadian Amiodarone Myocardial Infarction Trial) databases. The EMIAT and CAMIAT Investigators","volume":"99","author":"Boutitie","year":"1999","journal-title":"Circulation"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/0002-9149(94)90308-5","article-title":"Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators","volume":"74","author":"Kennedy","year":"1994","journal-title":"Am. J. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/0002-8703(86)90633-2","article-title":"The role of beta blocking agents as adjunct therapy to membrane stabilizing drugs in malignant ventricular arrhythmia","volume":"111","author":"Hirsowitz","year":"1986","journal-title":"Am. Heart J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0002-8703(95)90441-7","article-title":"Predictors of mortality in patients with sustained ventricular tachycardias or ventricular fibrillation and depressed left ventricular function: Importance of beta-blockade","volume":"130","author":"Crijns","year":"1995","journal-title":"Am. Heart J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"9I","DOI":"10.1016\/S0002-9149(98)00468-8","article-title":"Importance of beta blockade in the therapy of serious ventricular arrhythmias","volume":"82","author":"Reiter","year":"1998","journal-title":"Am. J. Cardiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"521","DOI":"10.4330\/wjc.v9.i6.521","article-title":"Management of ventricular tachycardia storm in patients with structural heart disease","volume":"9","author":"Muser","year":"2017","journal-title":"World J. Cardiol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1161\/01.CIR.102.7.742","article-title":"Treating electrical storm: Sympathetic blockade versus advanced cardiac life support-guided therapy","volume":"102","author":"Nademanee","year":"2000","journal-title":"Circulation"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.jacc.2018.02.056","article-title":"Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator","volume":"71","author":"Chatzidou","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3325\/cmj.2014.55.75","article-title":"Propranolol efficiency in prevention of sustained ventricular tachycardia in patients with implanted cardioverter-defibrillator: A case series","volume":"55","year":"2014","journal-title":"Croat. Med. J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0002-9149(89)90572-9","article-title":"Efficacy of intravenous propranolol for suppression of inducibility of ventricular tachyarrhythmias with different electrophysiologic characteristics in coronary artery disease","volume":"64","author":"Huikuri","year":"1989","journal-title":"Am. J. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1161\/CIRCULATIONAHA.108.829267","article-title":"Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia","volume":"119","author":"Hayashi","year":"2009","journal-title":"Circulation"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1161\/01.CIR.91.5.1512","article-title":"Catecholaminergic polymorphic ventricular tachycardia in children. A 7-year follow-up of 21 patients","volume":"91","author":"Leenhardt","year":"1995","journal-title":"Circulation"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/europace\/eut272","article-title":"Executive summary: HRS\/EHRA\/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes","volume":"15","author":"Priori","year":"2013","journal-title":"Europace"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/eurheartj\/6.suppl_D.103","article-title":"The idiopathic long QT syndrome: Pathogenetic mechanisms and therapy","volume":"6","author":"Schwartz","year":"1985","journal-title":"Eur. Heart J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1093\/europace\/euu086","article-title":"Effect of beta-blockers on QT dynamics in the long QT syndrome: Measuring the benefit","volume":"16","author":"Bennett","year":"2014","journal-title":"Europace"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCULATIONAHA.116.021823","article-title":"Clinical Aspects of Type 3 Long-QT Syndrome: An International Multicenter Study","volume":"134","author":"Wilde","year":"2016","journal-title":"Circulation"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"A61","DOI":"10.1016\/0002-9149(88)90741-2","article-title":"Overview of the clinical pharmacology of antiarrhythmic drugs","volume":"61","author":"Woosley","year":"1988","journal-title":"Am. J. Cardiol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"574","DOI":"10.7326\/0003-4819-111-7-574","article-title":"Amiodarone in patients with previous drug-mediated torsade de pointes. Long-term safety and efficacy","volume":"111","author":"Mattioni","year":"1989","journal-title":"Ann. Intern. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0735-1097(86)80272-8","article-title":"QT prolongation and the antiarrhythmic efficacy of amiodarone","volume":"7","author":"Torres","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(96)09145-3","article-title":"Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators","volume":"349","author":"Julian","year":"1997","journal-title":"Lancet"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0140-6736(96)08171-8","article-title":"Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators","volume":"349","author":"Cairns","year":"1997","journal-title":"Lancet"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"70F","DOI":"10.1016\/0002-9149(93)90966-G","article-title":"The CASCADE Study: Randomized antiarrhythmic drug therapy in survivors of cardiac arrest in Seattle. CASCADE Investigators","volume":"72","author":"Greene","year":"1993","journal-title":"Am. J. Cardiol."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Amiodarone Trials Meta-Analysis Investigators (1997). Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet, 350, 1417\u20131424.","DOI":"10.1016\/S0140-6736(97)05281-1"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1161\/CIRCULATIONAHA.111.072561","article-title":"Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: The ALPHEE study","volume":"124","author":"Kowey","year":"2011","journal-title":"Circulation"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1053\/euhj.2000.2476","article-title":"Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study","volume":"21","author":"Connolly","year":"2000","journal-title":"Eur. Heart J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.2165\/11200820-000000000-00000","article-title":"Dronedarone","volume":"69","author":"Hoy","year":"2009","journal-title":"Drugs"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/pds.5233","article-title":"Risk of interstitial lung disease in patients treated for atrial fibrillation with dronedarone versus other antiarrhythmics","volume":"30","author":"Tave","year":"2021","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ahj.2018.06.018","article-title":"Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs","volume":"205","author":"Friberg","year":"2018","journal-title":"Am. Heart J."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1056\/NEJMoa0800456","article-title":"Increased mortality after dronedarone therapy for severe heart failure","volume":"358","author":"McMurray","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1345\/aph.19185","article-title":"Dofetilide: A Class III-Specific Antiarrhythmic Agent","volume":"34","author":"Kalus","year":"2000","journal-title":"Ann. Pharmacother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1161\/01.CIR.102.21.2665","article-title":"Dofetilide","volume":"102","author":"Mounsey","year":"2000","journal-title":"Circulation"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1161\/01.CIR.102.19.2385","article-title":"Efficacy and Safety of Oral Dofetilide in Converting to and Maintaining Sinus Rhythm in Patients With Chronic Atrial Fibrillation or Atrial Flutter","volume":"102","author":"Singh","year":"2000","journal-title":"Circulation"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1540-8167.2011.02183.x","article-title":"Dofetilide Reduces the Frequency of Ventricular Arrhythmias and Implantable Cardioverter Defibrillator Therapies","volume":"23","author":"Baquero","year":"2012","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1056\/NEJM199909163411201","article-title":"Dofetilide in Patients with Congestive Heart Failure and Left Ventricular Dysfunction","volume":"341","author":"Egstrup","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1016\/S0140-6736(00)03402-4","article-title":"Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomised trial","volume":"356","author":"Thomsen","year":"2000","journal-title":"Lancet"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1540-8167.1995.tb00445.x","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Dofetilide in Patients with Inducible Sustained Ventricular Tachyarrhythmias","volume":"6","author":"Echt","year":"1995","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0002-9149(99)80293-8","article-title":"Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia","volume":"76","author":"Bashir","year":"1995","journal-title":"Am. J. Cardiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1053\/euhj.2001.2679","article-title":"A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease","volume":"22","author":"Boriani","year":"2001","journal-title":"Eur. Heart J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0002-8703(99)70484-9","article-title":"Sotalol: An important new antiarrhythmic","volume":"137","author":"Anderson","year":"1999","journal-title":"Am. Heart J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/0002-9149(91)90013-B","article-title":"Usefulness of d, I sotalol for suppression of chronic ventricular arrhythmias","volume":"67","author":"Gilbert","year":"1991","journal-title":"Am. J. Cardiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"A51","DOI":"10.1016\/0002-9149(93)90025-8","article-title":"Usefulness of sotalol for life-threatening ventricular arrhythmias","volume":"72","author":"Roden","year":"1993","journal-title":"Am. J. Cardiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1161\/01.CIR.92.6.1517","article-title":"Efficacy and Safety of d-Sotalol, a Pure Class III Antiarrhythmic Compound, in Patients With Symptomatic Complex Ventricular Ectopy","volume":"92","author":"Hohnloser","year":"1995","journal-title":"Circulation"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(96)02149-6","article-title":"Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction","volume":"348","author":"Waldo","year":"1996","journal-title":"Lancet"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJM199906173402402","article-title":"Prevention of Implantable-Defibrillator Shocks by Treatment with Sotalol","volume":"340","author":"Pacifico","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/01.CIR.86.1.29","article-title":"Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia","volume":"86","author":"Wichter","year":"1992","journal-title":"Circulation"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"B153","DOI":"10.1016\/0002-9149(87)90096-8","article-title":"Use of calcium antagonists for cardiac arrhythmias","volume":"59","author":"Singh","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/0002-9149(77)90074-1","article-title":"Effect of procainamide, propranolol and verapamil on mechanism of tachycardia in patients with chronic recurrent ventricular tachycardia","volume":"40","author":"Wellens","year":"1977","journal-title":"Am. J. Cardiol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0002-9149(84)80158-7","article-title":"Use of intravenous verapamil for ventricular tachycardia","volume":"54","author":"Belhassen","year":"1984","journal-title":"Am. J. Cardiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1136\/hrt.46.6.679","article-title":"Response of recurrent sustained ventricular tachycardia to verapamil","volume":"46","author":"Belhassen","year":"1981","journal-title":"Br. Heart J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/01.CIR.77.3.560","article-title":"Idiopathic sustained left ventricular tachycardia: Clinical and electrophysiologic characteristics","volume":"77","author":"Ohe","year":"1988","journal-title":"Circulation"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/S0735-1097(00)00780-4","article-title":"Demonstration of diastolic and presystolic purkinje potentials as critical potentials in a macroreentry circuit of verapamil-sensitive idiopathic left ventricular tachycardia","volume":"36","author":"Nogami","year":"2000","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_125","first-page":"175","article-title":"Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: State of the art and future developments","volume":"14","author":"Zwinderman","year":"2011","journal-title":"EP Eur."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.hrthm.2007.05.017","article-title":"Calcium channel blockers and beta-blockers versus beta-blockers alone for preventing exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia","volume":"4","author":"Rosso","year":"2007","journal-title":"Heart Rhythm"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/01.CIR.0000139333.83620.5D","article-title":"Electrophysiological Effects of Ranolazine, a Novel Antianginal Agent With Antiarrhythmic Properties","volume":"110","author":"Antzelevitch","year":"2004","journal-title":"Circulation"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"e003196","DOI":"10.1161\/JAHA.116.003196","article-title":"Ranolazine: A Contemporary Review","volume":"5","author":"Sedlak","year":"2016","journal-title":"J. Am. Heart Assoc"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jacc.2018.04.086","article-title":"Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial","volume":"72","author":"Zareba","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1111\/j.1540-8159.2011.03208.x","article-title":"Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks","volume":"34","author":"Bunch","year":"2011","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e004124","DOI":"10.1161\/CIRCHEARTFAILURE.117.004124","article-title":"Efficacy of Ranolazine in Patients with Symptomatic Hypertrophic Cardiomyopathy: The RESTYLE-HCM Randomized, Double-Blind, Placebo-Controlled Study","volume":"11","author":"Olivotto","year":"2018","journal-title":"Circ. Heart Fail"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1023\/A:1017991206635","article-title":"Right ventricular outflow tract tachycardia: An update","volume":"6","author":"Lerman","year":"2002","journal-title":"Card. Electrophysiol. Rev."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1161\/01.CIR.96.4.1192","article-title":"Adenosine-sensitive ventricular tachycardia: Right ventricular abnormalities delineated by magnetic resonance imaging","volume":"96","author":"Markowitz","year":"1997","journal-title":"Circulation"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"90","DOI":"10.15420\/AER.2016.4.3","article-title":"Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes","volume":"5","author":"Akdis","year":"2016","journal-title":"Arrhythm Electrophysiol. Rev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1111\/jce.12510","article-title":"Mechanism-specific effects of adenosine on ventricular tachycardia","volume":"25","author":"Lerman","year":"2014","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","author":"Group","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"h4451","DOI":"10.1136\/bmj.h4451","article-title":"Safety and efficacy of digoxin: Systematic review and meta-analysis of observational and controlled trial data","volume":"351","author":"Ziff","year":"2015","journal-title":"BMJ"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/eurheartj\/ehv143","article-title":"Digoxin-associated mortality: A systematic review and meta-analysis of the literature","volume":"36","author":"Vamos","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/CIRCHEARTFAILURE.115.002414","article-title":"Clinical Risk Stratification for Primary Prevention Implantable Cardioverter Defibrillators","volume":"8","author":"Lee","year":"2015","journal-title":"Circ. Heart Fail."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1016\/j.hrthm.2015.05.016","article-title":"Digoxin therapy and associated clinical outcomes in the MADIT-CRT trial","volume":"12","author":"Lee","year":"2015","journal-title":"Heart Rhythm"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1046\/j.1460-9592.2001.01293.x","article-title":"Successful prevention of recurrent ventricular fibrillation by intravenous isoproterenol in a patient with Brugada syndrome","volume":"24","author":"Tanaka","year":"2001","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.hrthm.2007.02.014","article-title":"Acute and chronic management in patients with Brugada syndrome associated with electrical storm of ventricular fibrillation","volume":"4","author":"Ohgo","year":"2007","journal-title":"Heart Rhythm"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1016\/j.jacc.2017.08.038","article-title":"The Clinical Use of Ivabradine","volume":"70","author":"Koruth","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure","volume":"371","author":"Fox","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2012.06.031","article-title":"Clinical Efficacy of Ivabradine in Patients With Inappropriate Sinus Tachycardia: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Crossover Evaluation","volume":"60","author":"Cappato","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/pace.13913","article-title":"Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy","volume":"43","author":"Kohli","year":"2020","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1111\/pace.13446","article-title":"Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia","volume":"41","author":"Vaksmann","year":"2018","journal-title":"Pacing Clin. Electrophysiol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1136\/heartjnl-2014-305482","article-title":"Atrial fibrillation associated with ivabradine treatment: Meta-analysis of randomised controlled trials","volume":"100","author":"Martin","year":"2014","journal-title":"Heart"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s12012-014-9274-y","article-title":"Torsades de Pointes Induced by the Concomitant Use of Ivabradine and Azithromycin: An Unexpected Dangerous Interaction","volume":"15","author":"Cocco","year":"2015","journal-title":"Cardiovasc. Toxicol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/11\/3233\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:24:56Z","timestamp":1760138696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/11\/3233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,6]]},"references-count":152,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["jcm11113233"],"URL":"https:\/\/doi.org\/10.3390\/jcm11113233","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,6]]}}}